Globus Medical to buy California life sciences firm for $250M
Montgomery County's Globus Medical has agreed to acquire a California life sciences company focused on treating chronic pain for $250 million in cash. Audubon-based Globus (NYSE: GMED) will pay $5.85 per share for Nevro Corp. (NYSE: NVRO), representing a 17% premium to the company's closing stocking price on Wednesday.
Jefferies analyst reiterated a Buy rating for Globus Medical (NYSE:GMED), with a steady price target of $105.00, following the company's announcement of its plans to acquire Nevro Corp . (NYSE:NVRO), ...
AUDUBON, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions ...
另一方面，Canaccord Genuity在公司公布2024年第四季度强劲初步业绩后，维持对Globus Medical的买入评级，并将目标价上调至101美元。Truist Securities虽然认可公司的优势，但维持对Globus Medical的持有评级，等待进一步的收入和每股收益增长证据。这些最新进展反映了公司的增长轨迹和Nevro Corp收购预期带来的收益。
Jefferies upgraded Nevro (NVRO) to Hold from Underperform with a price target of $5.85, up from $4.50, after the company entered into a ...
On a stand-alone basis, Globus Medical (GMED) reaffirms guidance for 2025 net sales of $2.66B to $2.69B and fully diluted non-GAAP earnings per ...
周四，在Globus Medical (NYSE: GMED )宣布以约2.5亿美元股权价值收购Nevro Corp. (NVRO)后，Stifel分析师维持该公司股票的买入评级和92.00美元的目标价。根据InvestingPro数据，Globus Medical保持着优秀的财务状况，整体评分为"优秀"，流动性指标强劲。此次交易导致Globus Medical修改了2025年每股收益 ...
Baird raised the firm’s price target on Nevro (NVRO) to $5.85 from $5 and keeps a Neutral rating on the shares. The firm noted its acquisition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback